Page 43 - Genentech News Today

People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.

People without memory problems could be diagnosed with Alzheimer's under a plan by an influential scientific panel dominated by members with ties to drug companies.

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investiga

Biogen's Leqembi launch challenges impact stock growth; Spinraza faces competition. Analyst lowers price target to $316, citing uncertainties.

This review summarizes current utilization of anti-HER2 targeted therapy across several non-breast solid tumors in the setting of advanced disease.

A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investiga

Tuesday, Biogen Inc (NASDAQ:BIIB) posted fourth-quarter 2023 sales of $2.39 billion, missing the consensus of $2.46 billion, down 6% Y/Y and 5% at constant currency (CC). Adjusted EPS of $2.95, down 27%, missing the consensus of $3.18. Biogen’s partner, Eisai Co Ltd (OTC:ESALY), has faced a delay in reaching the 10,000-patient mark for Leqembi despite strong demand. In its third quarter financial results, Eisai disclosed that as of January 26, 2,000 patients were on treatment, with an est...

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTDs companion...

St. Charles Foundation's annual Saints Gala co-sponsored by Genentech and CORA was a resounding success, raising nearly half a million dollars to enable St.

The DOSED Clinical Study Will Evaluate a Novel Delivery Device in Subacute and Chronic Spinal Cord Injury Patients ...